Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Non Operating Income (2016 - 2026)

Ani Pharmaceuticals' Non Operating Income history spans 14 years, with the latest figure at $850000.0 for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 161.68% to $850000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 147.95% increase, with the full-year FY2025 number at $1.9 million, up 147.95% from a year prior.
  • Non Operating Income hit $850000.0 in Q4 2025 for Ani Pharmaceuticals, up from -$853000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for ANIP hit a ceiling of $1.7 million in Q2 2025 and a floor of -$2.7 million in Q4 2021.
  • Historically, Non Operating Income has averaged -$296550.0 across 5 years, with a median of -$47500.0 in 2022.
  • Biggest five-year swings in Non Operating Income: tumbled 6400.0% in 2024 and later skyrocketed 2076.14% in 2025.
  • Tracing ANIP's Non Operating Income over 5 years: stood at -$2.7 million in 2021, then soared by 98.44% to -$42000.0 in 2022, then increased by 21.43% to -$33000.0 in 2023, then plummeted by 4075.76% to -$1.4 million in 2024, then skyrocketed by 161.68% to $850000.0 in 2025.
  • Business Quant data shows Non Operating Income for ANIP at $850000.0 in Q4 2025, -$853000.0 in Q3 2025, and $1.7 million in Q2 2025.